Miller Fisher Syndrome Diagnosis and Management

Diagnostic Criteria

The American Academy of Neurology recommends that Miller Fisher Syndrome (MFS) be diagnosed based on the classical triad of ophthalmoplegia, ataxia, and areflexia, with confirmation through anti-GQ1b antibody testing and supportive cerebrospinal fluid findings 1, 2
The clinical triad of MFS consists of ophthalmoplegia (eye movement abnormalities), ataxia (difficulty with coordination and balance), and areflexia (reduced or absent deep tendon reflexes) 1, 2
Incomplete forms of MFS may occur with isolated ataxia (acute ataxic neuropathy) or ophthalmoplegia (acute ophthalmoplegia) 1

The American Academy of Neurology recommends intravenous immunoglobulin (IVIG) as a first-line treatment for MFS, with a recommended dosage of 0.4 g/kg/day for 5 days (total dose 2 g/kg) 2
Plasmapheresis (plasma exchange) is an alternative to IVIG with similar efficacy, typically performed over 5 days 2
Corticosteroids are not recommended as monotherapy, but may be considered in combination with IVIG in severe cases 2

The prognosis for MFS is generally favorable, with a case fatality rate <5% and most patients recovering within weeks to months 1, 2
Overlap with classical Guillain-Barré syndrome occurs in approximately 15% of patients 1, 2
MFS accounts for 5-25% of all Guillain-Barré syndrome cases 1, 2

Regular monitoring of respiratory function, including vital capacity measurements, is recommended, with 15-30% of cases requiring ventilatory support 2
Daily neurological assessments are necessary to track disease progression 2